Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Avistone Biotech Approved to Launch c-Met Inhibitor for NSCLC with Genetic Mutations

publication date: Nov 16, 2023

Beijing Avistone Biotechnology was conditionally approved to launch vebreltinib, a novel small molecule therapy for MET exon 14 skipping non-small cell lung cancer (NSCLC) in China. Avistone in-licensed the drug from Apollomics of Foster City, CA, which has filed for US approval of the candidate. Vebreltinib is a small molecule, selective c-Met inhibitor that activates the HGF/c-Met axis, a pathway involved in tumor growth, proliferation and resistance to targeted therapies. About 3% to 4% of all NSCLC patients have MET exon 14 skipping mutations. More details....

Stock Symbol: (NSDQ: APLM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital